scholarly journals Sentinel lymph node mapping in endometrial cancer: a systematic review and meta-analysis

Oncotarget ◽  
2017 ◽  
Vol 8 (28) ◽  
pp. 46601-46610 ◽  
Author(s):  
Hefeng Lin ◽  
Zheyuan Ding ◽  
Vishnu Goutham Kota ◽  
Xiaoming Zhang ◽  
Jianwei Zhou
Keyword(s):  
Systematic Review ◽  
Endometrial Cancer ◽  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Meta Analysis ◽  
Sentinel Lymph Node Mapping ◽  
Lymph Node Mapping

scholarly journals Prognostic Significance of Sentinel Lymph Node Mapping in Merkel Cell Carcinoma: Systematic Review and Meta-Analysis of Prognostic Studies

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Ramin Sadeghi ◽  
Zohreh Adinehpoor ◽  
Masoud Maleki ◽  
Babak Fallahi ◽  
Luca Giovanella ◽  
...  
Keyword(s):  
Systematic Review ◽  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Meta Analysis ◽  
Sentinel Lymph Node Mapping ◽  
Merkel Cell ◽  
Prognostic Information ◽  
Lymph Node Mapping

Aim.To assess through a systematic review and meta-analysis of the literature the prognostic implication of sentinel lymph node mapping in Merkel cell carcinoma (MCC).Materials and Methods.PubMed and SCOPUS databases were searched by using “Merkel AND sentinel” as keywords. All studies with prognostic information regarding SLN mapping in cN0 MCC patients were included. Hazard ratio (HR) for overall survival (OS) and disease free survival (DFS) was used as effect size.Results.SLN biopsy predicted better DFS and OS as compared to the nodal observation in cN0 MCC patients (pooled HR for DFS: 1.61 (95% CI: 1.05–2.46),P=0.028; pooled HR for OS: 1.08 (95% CI: 0.55–2.10),P=0.8). Pathologically negative SLN (SLN−) patients had better OS (pooled HR: 4.42 (95% CI: 1.82–10.7),P=0.0009) and DFS (pooled HR: 2.58 (95% CI: 1.78–3.73)) as compared to SLN+ patients.Conclusion.SLN mapping can provide strong prognostic information regarding OS and DFS in cN0 MCC patients. More importantly, SLN mapping can improve DFS and possibly OS in cN0 MCC patients as compared to nodal observation. As MCC is a rare tumor, large multicenter prospective studies are still needed to validate the survival benefit of SLN mapping.

Sign in / Sign up

Export Citation Format

Share Document